U.S. Reclassifies FDA-Approved, State-Licensed Medical Marijuana as Less Dangerous Drug, Marking Major Policy Shift

WASHINGTON D.C. — In a historic departure from five decades of federal drug policy, the U.S. Department of Justice (DOJ) announced on April 23, 2026, that it has officially reclassified FDA-approved and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act. The move, signed by Acting Attorney General Todd Blanche under President Donald Trump’s administration, formally recognizes marijuana’s medical utility and lower potential for abuse when used under professional supervision. While the order does not legalize recreational use nationwide, it effectively dismantles significant federal barriers to medical research and tax equity for the cannabis industry in the 40 states where medical programs currently exist.

A New Era for Federal Oversight

Since 1970, marijuana has been classified alongside substances like heroin and LSD under Schedule I—a category reserved for drugs with “no currently accepted medical use” and a high potential for abuse. This classification has long been a point of contention for scientists, patients, and state regulators who argued that the federal stance ignored a growing body of clinical evidence.

The new DOJ order shifts FDA-approved cannabis products and those dispensed through state-licensed medical programs into Schedule III. This category includes substances like ketamine and anabolic steroids, which are considered to have a “moderate to low potential for physical and psychological dependence.”

For the healthcare industry and state-sanctioned businesses, the implications are immediate:

• Tax Relief: Under Internal Revenue Code Section 280E, businesses dealing in Schedule I or II substances were previously barred from deducting ordinary business expenses. Reclassification to Schedule III removes this “tax penalty,” potentially saving the medical cannabis industry billions of dollars annually.

• Research Expansion: Researchers will no longer face the onerous registration requirements mandated by the DEA for Schedule I substances, which many experts believe has stifled clinical trials for decades.

• Regulatory Alignment: The move aligns federal policy with the 40 states (and the District of Columbia) that have already legalized marijuana for medical purposes.

The Clinical Evidence: Moving Beyond Anecdotes

The reclassification is rooted in a 2023 scientific review by the Department of Health and Human Services (HHS) and the FDA, which concluded that cannabis has a currently accepted medical use in the U.S. This review analyzed thousands of peer-reviewed studies and clinical trials.

Medical marijuana consists of various compounds, most notably delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). According to the Cleveland Clinic and Mayo Clinic, rigorous meta-analyses support its use in several specific areas:

1. Chronic and Neuropathic Pain: Small to moderate pain relief has been observed in patients with nerve damage or long-term pain conditions, though doctors note that side effects like dizziness must be managed.

2. Chemotherapy-Induced Nausea: Cannabis-based treatments have shown significant efficacy for patients who do not respond to standard anti-emetics.

3. Multiple Sclerosis (MS): Evidence suggests that oral sprays containing THC and CBD can reduce muscle spasticity and improve quality of life for MS patients.

“This change is a long-overdue acknowledgment of the clinical reality,” said Dr. Nora Volkow, director of the National Institute on Drug Abuse (NIDA). “Aligning federal policy with what science shows about marijuana’s medical utility allows us to treat it with the same rigorous scientific scrutiny as any other medicine.”

Expert Perspectives: Progress with Precaution

While the medical community has largely welcomed the shift, experts caution against viewing the reclassification as a sign that marijuana is “risk-free.”

Dr. Kevin Hill, a psychiatrist and addiction specialist at Brigham and Women’s Hospital, emphasizes the nuance of the Schedule III designation. “Schedule III still means this is a drug with abuse potential,” Hill noted in an interview with Stat News. “This is an opportunity to generate better data, not to assume that cannabis is harmless. Patients should not interpret this as a license to self-medicate without professional guidance.”

Furthermore, some public health experts worry about the message this sends to younger populations. “There is a risk that downgrading the classification could normalize use among adolescents, whose developing brains are particularly vulnerable to the effects of THC,” warned representatives from the American Academy of Pediatrics in previous policy discussions.

Implications for Public Health and Safety

The most significant public health benefit may be the shift toward a regulated market. By validating state-licensed medical channels, the DOJ is incentivizing patients to move away from the “black market,” where products are often tainted with pesticides, heavy metals, or synthetic additives.

Under Schedule III, the DEA will maintain oversight of security, labeling, and disposal rules, but the focus will shift toward standardizing quality. This could lead to:

• Standardized Dosing: Improved research may finally provide clinicians with clear dosing guidelines, which currently vary wildly between states.

• Safety Monitoring: A federal framework allows for better tracking of adverse reactions and drug-drug interactions.

Limitations and the Path Ahead

Despite the significance of the move, the reclassification is narrowly tailored. It does not apply to recreational (adult-use) marijuana, which remains Schedule I under federal law. This creates a complex legal “dual-track” system where the same plant is treated differently depending on the user’s intent and the license of the seller.

Advocacy groups like NORML have stated that while this is a “historic step,” it falls short of full descheduling. “Medical cannabis programs have been operating safely for years,” a NORML spokesperson stated. “But as long as marijuana remains on the Controlled Substances Act, the risk of federal interference remains for those outside the narrow medical definitions.”

Conservative groups have also voiced opposition, arguing that the reclassification conflicts with federal messages regarding substance abuse prevention and may lead to increased rates of Cannabis Use Disorder (CUD).

What This Means for Patients

For the average patient, the transition will likely be subtle at first. State-issued medical cards remain the primary vehicle for access. However, patients should expect their physicians to be more open to discussing cannabis as a therapeutic option.

Key recommendations for patients include:

• Consultation: Always use cannabis under the supervision of a healthcare provider.

• Interaction Awareness: Discuss how cannabis may interact with blood thinners, sedatives, or psychiatric medications.

• Safety First: Avoid operating heavy machinery or driving while using THC-containing products.

As federal agencies begin the complex task of coordinating with 40 different state systems, the healthcare landscape is set for a period of rapid evolution. For millions of Americans, the “medicine” they have used for years is finally, in the eyes of the federal government, officially medicinal.

Reference Section

• Reuters. “DOJ reclassifies FDA-approved, state-licensed marijuana as less dangerous drug.” April 23, 2026.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.